UBS Group
ANIK icon

UBS Group’s Anika Therapeutics ANIK Stock Holding History

UBS Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-800
Closed -$33K – 8456
2015
Q1 		$33K Sell
800
-100
-11% -$4.04K ﹤0.01% 6448
2014
Q4 		$37K Buy
+900
New +$35.2K ﹤0.01% 6855

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

UBS Group's ANIK Position: Q2 2026 in Review

UBS Group increased its Anika Therapeutics (ANIK) stake by 9.6% in Q2 2026, buying an estimated $189K and bringing the position to 145,816 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5062.

UBS Group first reported a position in ANIK in Q4 2014 and has held it in 47 quarters since. The position peaked at $3.3M in Q1 2019. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • UBS Group held 145,816 shares of Anika Therapeutics worth $2.13M as of Q2 2026.
  • UBS Group bought 12,742 Anika Therapeutics shares in Q2 2026, an estimated $189K.
  • Anika Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5062 holding.
  • UBS Group first reported a position in Anika Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Anika Therapeutics position peaked at $3.3M in Q1 2019.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.